Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4...

por Schmidinger, M., Shariat, S.F., Fajkovic, H.
Publicado 2021

804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)

por Albiges, L., Schmidinger, M., Taguieva-Pioger, N., Perol, D., Gruenwald, V.
Publicado 2020

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines

por Resch, I., Bruchbacher, A., Franke, J., Fajkovic, H., Remzi, M., Shariat, S.F., Schmidinger, M.
Publicado 2021

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

por Vogl, U M, Zehetgruber, H, Dominkus, M, Hejna, M, Zielinski, C C, Haitel, A, Schmidinger, M
Publicado 2006

Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

por Schmidinger, M, Wenzel, C, Locker, G J, Muehlbacher, F, Steininger, R, Gnant, M, Crevenna, R, Budinsky, A C
Publicado 2001

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

por Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Uemura, H., Albiges, L., Fujii, Y., Umeyama, Y., Wang, J., Mariani, M., Schmidinger, M.
Publicado 2022

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

por Steindl, A., Alpar, D., Heller, G., Mair, M.J., Gatterbauer, B., Dieckmann, K., Widhalm, G., Hainfellner, J.A., Schmidinger, M., Bock, C., Müllauer, L., Preusser, M., Berghoff, A.S.
Publicado 2021

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

por Aeppli, S., Schmaus, M., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B.I., Schmidinger, M., Sternberg, C.N., Rothermundt, C., Putora, P.M.
Publicado 2021

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris...

por Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.
Publicado 2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

por Kanesvaran, R., Porta, C., Wong, A., Powles, T., Ng, Q.S., Schmidinger, M., Ye, D., Malhotra, H., Miura, Y., Lee, J.L., Chong, F.L.T., Pu, Y.-S., Yen, C.-C., Saad, M., Lee, H.J., Kitamura, H., Bhattacharyya, G.S., Curigliano, G., Poon, E., Choo, S.P., Peters, S., Lim, E., Yoshino, T., Pentheroudakis, G.
Publicado 2021

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

por Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Publicado 2020